17th March 2022 | Pharma Updates
Idelalisib has been approved by the CDSCO for manufacture and marketing
Natco Pharma has received approval from the CDSCO’s Subject Expert Committee (SEC) to commercialise and produce Idelalisib tablets, an antineoplastic kinase inhibitor.
Bharat Biotech is teaming with Biofabri to develop a new tuberculosis vaccine
Bharat Biotech and Biofabri, a Spanish biopharmaceutical company, have announced a collaboration to research, manufacture, and commercialise a new tuberculosis vaccine.
Philips' Capsule Surveillance solution has received FDA 510(k) clearance
USFDA has given Royal Philips’ newest Capsule Surveillance solution 510(k) clearance. Virtually any linked medical gadget can be used with the new solution.
Adagene Receives FDA Approval to Continue Combination Therapy
Adagene received FDA approval to proceed with a Phase 1b/2 clinical trial of ADG126, an anti-CTLA-4 monoclonal antibody (mAb), in association with pembrolizumab, an anti-PD-1 antibody.
Immunotherapy for advanced lung cancer is increasing people's survival rates
Immunotherapy, in contrast to therapies like chemotherapy and radiation therapy, which destroy cells, aids the body’s natural defences in battling lung cancer.
NIH has begun clinical trial of three mRNA HIV vaccines
(NIAID), part of NIH, has begun phase-I clinical trial to evaluate three experimental HIV vaccines based on a messenger RNA (mRNA) platform, which is similar to the technology used in several approved COVID-19 vaccines.
The Biotech company celebrates its first FDA Approval
The company’s Investigational New Drug application for SON-1010 has been approved by the USFDA. Sonnet will begin its First-in-Human Phase 1 trial in adult oncology patients in the second quarter of 2022.
Breyna Abbreviated NDA receives FDA approval
USFDA has given Mylan Pharmaceuticals, a Viatris subsidiary, clearance for its Abbreviated New Drug Application for Breyna, the first approved generic equivalent of AstraZeneca PLC’s Symbicort.
RINVOQ (upadacitinib) has been approved by the FDA
RINVOQ has been approved by the USFDA for the treatment of people with moderately to highly active ulcerative colitis (UC) who have had a poor response or intolerance to one or more tumour necrosis factor (TNF) blockers.
WHO: New COVID deaths decreased by 17% last week, but cases increased
According to the WHO, the number of new coronavirus deaths recorded worldwide decreased by 17% last week, but COVID-19 infections increased, reversing a trend that began in January.
and then